BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's ...

Investors buying this biotech stock now will get its pipeline essentially for free.

Pfizer Canada ULC and BioNTech SE today announced that Health Canada has authorized the XFG variant-adapted COMIRNATY® for active immunization of individuals aged 6 months and older against COVID-19.

BioNTech SE (NASDAQ:BNTX) is ending a mid-stage study of its personalized mRNA cancer vaccine, autogene cevumeran, after an independent monitoring committee concluded that continuing the trial was ...

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual ...

COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating ...

BioNTech SE and Roche Holding AG abandoned a trial of a personalized cancer vaccine, dashing hopes that had been raised by a rival drugmaker’s recent success in the field.

For BioNTech, the readout offers tangible evidence that its pivot toward oncology is producing results rather than just promises. The company has spent years signaling its intent to move beyond ...

BioNTech reported surprisingly strong sales of its COVID-19 vaccine in the third quarter, which reached €1.24 billion ($1.35 billion) and more than doubled the consensus estimate of $652 million. It ...

BioNTech (NASDAQ:BNTX) announced Friday two separate agreements worth more than $1B with the National Institutes of Health (NIH) and the University of Pennsylvania to resolve royalty and other claims ...

BioNTech (NasdaqGS:BNTX) moved after fresh clinical news, as investors reacted to detailed Phase 3 data showing its ...